- Basilea Pharmaceutica ( OTC:BPMUF ) expects an operating profit of about CHF18M and also anticipates net profit, for the financial year 2022 as per preliminary results.
- The Swiss company had previously guided for an operating loss of CHF10M to CHF15M for 2022.
- "Our strong 2022 financial performance is the result of the successful implementation of our strategic decision to focus on anti-infectives in combination with the continued commercial success of our marketed brands," said CFO Adesh Kaul.
- Basilea noted that in earlier in January it reported total revenue for 2022 is expected to be about CHF148M, exceeding the prior guidance of CHF116M to CHF122M.
- The company is scheduled to publish financial statements and the annual report 2022 on Feb. 14.
For further details see:
Basilea sees preliminary FY22 operating profit above outlook